In support of this assumption, we found that MYBL2, but not ETS1, is co-expressed with EIF4EBP1 at the mRNA level in a variety of non-CNS cancer entities, suggesting that MYBL2 might represent a general transcriptional driver of EIF4EBP1 overexpression in human cancers while ETS1-dependent regulation of EIF4EBP1 may be more restricted to CNS tumors. Here, MYBL2 is linked to central nervous system cancer.